Mulat Zerihun
Overview
Explore the profile of Mulat Zerihun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lynn M, Ayele Z, Chernet A, Goodhew E, Wickens K, Sata E, et al.
PLoS Negl Trop Dis
. 2025 Mar;
19(3):e0012900.
PMID: 40067808
Background: Persistent trachoma is increasingly recognized as a serious concern for the global trachoma program. Persistent trachoma is defined as those districts that have had two or more trachoma impact...
2.
Nash S, Sata E, Chernet A, Gonzalez T, Nute A, Ontiveros V, et al.
Am J Trop Med Hyg
. 2024 Jul;
111(3_Suppl):105-113.
PMID: 38955191
Persistent trachoma is a growing concern to trachoma control programs globally and programs serving Ethiopia specifically. Persistent trachoma is defined as a district with two or more trachoma impact surveys...
3.
Sata E, Seife F, Ayele Z, Murray S, Wickens K, Le P, et al.
PLoS Negl Trop Dis
. 2024 Feb;
18(2):e0011986.
PMID: 38386689
Background: Trachoma recrudescence after elimination as a public health problem has been reached is a concern for control programs globally. Programs typically conduct district-level trachoma surveillance surveys (TSS) ≥ 2...
4.
Mahmud H, Haile B, Tadesse Z, Gebresillasie S, Shiferaw A, Zerihun M, et al.
Clin Infect Dis
. 2023 Apr;
77(3):388-395.
PMID: 37021692
Background: Current guidelines recommend annual community-wide mass administration of azithromycin for trachoma. Targeting treatments to those most likely to be infected could reduce the amount of unnecessary antibiotics distributed. Methods:...
5.
Nash S, Chernet A, Weiss P, Nute A, Zerihun M, Sata E, et al.
Am J Trop Med Hyg
. 2023 Jan;
108(2):261-267.
PMID: 36623484
Although trachoma mass drug administration (MDA) programs target ocular Chlamydia trachomatis, the global trachoma control program does not monitor infection as a measure of impact but instead relies on monitoring...
6.
Mosenia A, Haile B, Shiferaw A, Gebresillasie S, Gebre T, Zerihun M, et al.
Clin Infect Dis
. 2022 Dec;
76(6):1038-1042.
PMID: 36477547
Background: Mass administration of azithromycin is an established strategy for decreasing the prevalence of trachoma in endemic areas. However, nearby untreated communities could serve as a reservoir that may increase...
7.
Whitson C, Nute A, Hailemariam B, Deathe A, Astale T, Ayele Z, et al.
Trans R Soc Trop Med Hyg
. 2022 Sep;
117(2):111-117.
PMID: 36162054
Background: As countries reach the trachoma elimination threshold and cases of trachomatous inflammation follicular (TF) become rare, it becomes difficult to train survey graders to recognize clinical signs. We assess...
8.
Hailemariam B, Sata E, Halefom M, Deathe A, Zerihun M, Jensen K, et al.
J Infect Dev Ctries
. 2022 Sep;
16(8.1):8S-14S.
PMID: 36156496
Introduction: Trachomatous trichiasis (TT) is the advanced stage of trachoma where lashes touch the globe of the eye causing permanent damage. Without eyelid surgery, TT can lead to irreversible blindness....
9.
Gallini J, Sata E, Zerihun M, Melak B, Haile M, Zeru T, et al.
Int J Infect Dis
. 2021 Dec;
116:101-107.
PMID: 34965463
Objectives: The World Health Organization recommends mass drug administration (MDA) with azithromycin to eliminate trachoma as a public health problem. MDA decisions are based on prevalence estimates from two-stage cluster...
10.
Nash S, Chernet A, Astale T, Sata E, Zerihun M, Nute A, et al.
Am J Trop Med Hyg
. 2021 Oct;
106(1):62-65.
PMID: 34695789
Infants ages < 6 months do not receive azithromycin as part of trachoma control and thus may serve as an infection reservoir in persistently endemic districts. The aim of this...